The stock of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) is a huge mover today! About 142,562 shares traded hands. Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has risen 20.94% since March 3, 2016 and is uptrending. It has outperformed by 12.59% the S&P500.
The move comes after 7 months positive chart setup for the $98.89M company. It was reported on Oct, 6 by Barchart.com. We have $15.07 PT which if reached, will make NASDAQ:CATB worth $172.07 million more.
Analysts await Catabasis Pharmaceuticals Inc (NASDAQ:CATB) to report earnings on November, 10. They expect $-0.64 earnings per share, down 16.36% or $0.09 from last year’s $-0.55 per share. After $-0.61 actual earnings per share reported by Catabasis Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 4.92% negative EPS growth.
Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Ratings Coverage
Out of 2 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Catabasis Pharmaceuticals has been the topic of 4 analyst reports since August 17, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Citigroup given on Tuesday, March 22. The rating was maintained by Wedbush with “Buy” on Monday, August 17. Citigroup maintained it with “Buy” rating and $8 target price in Thursday, June 9 report. Wedbush maintained Catabasis Pharmaceuticals Inc (NASDAQ:CATB) rating on Wednesday, June 8. Wedbush has “Outperform” rating and $17 price target.
According to Zacks Investment Research, “Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.”
More notable recent Catabasis Pharmaceuticals Inc (NASDAQ:CATB) news were published by: Businesswire.com which released: “Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research …” on September 29, 2016, also Businesswire.com with their article: “Catabasis Pharmaceuticals Announces Closing of $11.5 Million Offering of …” published on September 28, 2016, Schaeffersresearch.com published: “Analyst Update: Catabasis Pharmaceuticals Inc, Coach Inc, and Lululemon …” on September 29, 2016. More interesting news about Catabasis Pharmaceuticals Inc (NASDAQ:CATB) were released by: Schaeffersresearch.com and their article: “Buzz Stocks: Catabasis Pharmaceuticals Inc, NXP Semiconductors NV, and …” published on September 30, 2016 as well as Businesswire.com‘s news article titled: “Catabasis Pharmaceuticals Announces Promotion of Andrew Nichols, Ph.D. to …” with publication date: October 05, 2016.
CATB Company Profile
Catabasis Pharmaceuticals, Inc., incorporated on June 26, 2008, is a clinical-stage biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company’s primary focus is on treatments for rare diseases. The Firm is also developing other product candidates for the treatment of lipid disorders. The Company’s CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. The Company’s CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company’s CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.